NEW YORK (GenomeWeb News) – Sequenom said today that it has obtained exclusive rights to Genomic Nanosystems’ digital PCR technologies and techniques.
The agreement gives Sequenom exclusive rights to use the digital PCR methods for non-invasive, prenatal diagnostic testing and sample analysis on any platform. In addition, the company will have exclusive rights to use digital PCR in conjunction with mass spectrometry for all commercial, diagnostic, or research applications except second-generation sequencing.
In a statement issued today, Sequenom CEO Harry Stylli said that the agreement — and another digital PCR licensing agreement signed last week — serve to enhance Sequenom’s intellectual property position for non-invasive prenatal diagnostic testing. He also noted that the company plans to develop a system that combines its proprietary MassARRAY system with digital PCR for use in other areas, including the genomic analysis business and cancer research and diagnostics.
Financial terms of the agreement were not disclosed.
Genomic Nanosystems is a wholly owned subsidiary of Cytonix Corporation.